<table border="1" id="table_12" rules="all" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption id="id_51336891-71bd-4af0-b6e1-b40491cf3a06">Table 12. Virologic Response (HIV-1 RNA &lt;400 copies/mL) at Week 48 by Baseline KALETRA Susceptibility and by Number of Protease Substitutions Associated with Reduced Response to KALETRA<sup>1</sup>
</caption>
<col width="4243*"></col>
<col width="4509*"></col>
<col width="4244*"></col>
<col width="NaN%"></col>
<tbody>
<tr id="id_772fde5d-26fa-4113-a7f5-34cbddab48b0">
<td align="left" stylecode="Lrule Toprule" valign="top">
<content stylecode="bold">Number of protease inhibitor substitutions at baseline<sup>1</sup>
</content>
</td>
<td align="center" stylecode="Toprule" valign="top">
<content stylecode="bold">Study 888 (Single protease inhibitor-experienced<sup>2</sup>, NNRTI-naïve) n=130</content>
</td>
<td align="center" stylecode="Toprule" valign="top">
<content stylecode="bold">Study 765 (Single protease inhibitor-experienced<sup>3</sup>, NNRTI-naïve) n=56</content>
</td>
<td align="center" stylecode="Rrule" valign="top">
<content stylecode="bold">Study 957 (Multiple protease inhibitor-experienced<sup>4</sup>, NNRTI-naïve) n=50</content>
</td>
</tr>
<tr id="id_8c240abf-a188-46b2-83e2-963b55479363">
<td align="left" stylecode="Lrule" valign="top">0-2</td>
<td align="center" valign="top">76/103 (74%)</td>
<td align="center" valign="top">34/45 (76%)</td>
<td align="center" stylecode="Rrule" valign="top">19/20 (95%)</td>
</tr>
<tr id="id_069f675e-1cab-43ec-8fdb-0081ab78f7fd">
<td align="left" stylecode="Lrule" valign="top">3-5</td>
<td align="center" valign="top">13/26 (50%)</td>
<td align="center" valign="top">8/11 (73%)</td>
<td align="center" stylecode="Rrule" valign="top">18/26 (69%)</td>
</tr>
<tr id="id_946dcf77-bb76-4beb-a3e4-3c1ed5fc638a">
<td align="left" stylecode="Lrule" valign="top">6 or more</td>
<td align="center" valign="top">0/1 (0%)</td>
<td align="center" valign="top">N/A</td>
<td align="center" stylecode="Rrule" valign="top">1/4 (25%)</td>
</tr>
<tr id="id_4c33b55e-ab7a-4378-a457-9414bea4f618">
<td align="left" colspan="4" stylecode="Lrule Botrule Rrule" valign="top">1   Substitutions considered in the analysis included L10F/I/R/V, K20M/N/R, L24I, L33F, M36I, I47V, G48V, I54L/T/V, V82A/C/F/S/T, and I84V.<br/>2   43% indinavir, 42% nelfinavir, 10% ritonavir, 15% saquinavir.<br/>3   41% indinavir, 38% nelfinavir, 4% ritonavir, 16% saquinavir.<br/>4   86% indinavir, 54% nelfinavir, 80% ritonavir, 70% saquinavir.</td>
</tr>
</tbody>
</table>